Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 14, 2023

Adjuvant Osimertinib for Resected Stage IB–IIIA EGFR-Mutated NSCLC: 3-Year Safety, Tolerability, and HRQoL Outcomes

Journal of Thoracic Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients with Resected Stage IB-IIIA EGFR-Mutated Non-Small Cell Lung Cancer: Updated Analysis from the Phase 3 ADAURA Trial
J Thorac Oncol 2023 May 24;[EPub Ahead of Print], T John, C Grohé, JW Goldman, FA Shepherd, F de Marinis, T Kato, Q Wang, WC Su, JH Choi, V Sriuranpong, B Melotti, MJ Fidler, J Chen, M Albayaty, M Stachowiak, S Taggart, YL Wu, M Tsuboi, RS Herbst, M Majem

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading